Información del artículo
Suplemento especial
Este artículo forma parte de:
Efectos secundarios de las vacunas contra el COVID-19 - Side effects of COVID-19 vaccines
Editado por: Dra. Núria Torner CIBER Epidemiologia y Salud Publica CIBERESP Unitat de Medicina Preventiva i Salut Pública Departament de Medicina, Universitat de Barcelona
Última actualización: Julio 2024
Más datosResumen
Introducción
la presente revisión se centra en la estimulación inmunitaria innata-adaptativa por las vacunas COVID-19, especialmente por las vacunas ARNm-iLNP. Se describen las tecnologías iLNP y ARNm modificado con nucleósidos, la transcripción inversa, las señales inflamatorias vinculadas a la reactogenicidad, incluye la diafonía vascular mediada por el factor de crecimiento endotelial vascular (VEGF), inducida por la proteína pico con efecto sistémico y que imitan el COVID-persistente. Por último, se discuten en detalle la conexión entre la manifestación de las formas graves de las reacciones adversas a la vacunación y el mimetismo molecular, la producción de autoanticuerpos particulares y el papel de ciertos adyuvantes de las vacunas.
Objetivosidentificar los artículos que publican información sobre los efectos adversos producidos después de la administración de las vacunas COVID-19 para demostrar su potencial terapéutico en el tratamiento y/o prevención de la enfermedad; así como evidenciar la asociación de causalidad y ocurrencia temporal.
Metodologíarevisión sistemática de la literatura científica publicada entre julio de 2021 y julio de 2023, que analiza todos los reportes sobre firmas inflamatorias de efectos adversos graves causados por las vacunas contra el COVID-19.
Resultadosla revisión sistemática ha permitido identificar 2033 registros que, tras un proceso de cribado de acuerdo con los criterios de inclusión y la eliminación de trabajos duplicados, de trabajos con problemas metodológicos y de trabajos sin acceso libre, se redujeron a 58 artículos; de ellos, 50 artículos son modelos humanos y 2 corresponden a modelos celulares.
Conclusiónlos resultados de esta revisión revelan la asociación causal y temporal de los distintos efectos adversos graves posteriores a la administración de las vacunas COVID-19 y se reconoce el «efecto de pico» de las vacunas COVID-19.
Palabras clave:
Vacuna COVID-19
Eventos adversos
Vacuna SARS-CoV-2
Abstract
Introduction
The present review focuses on innate-adaptative immune stimulation by COVID-19 vaccines, especially by mRNA-iLNP vaccines. It describes iLNP and nucleoside-modified mRNA technologies, reverse transcription, inflammatory signals linked to reactogenicity, including vascular endothelial growth factor (VEGF)-mediated vascular crosstalk, induced by systemic and spike protein, which mimic COVID-persistent. Finally, the connection between the manifestation of severe forms of adverse reactions to vaccination and molecular mimicry, the production of particular autoantibodies and the role of certain vaccine adjuvants are discussed in detail.
ObjectivesTo identify articles that publish information on the adverse effects produced after the administration of COVID-19 vaccines in order to demonstrate their therapeutic potential in the treatment-prevention of disease; as well as to demonstrate the association of causality and temporal occurrence.
MethodologySystematic review of the scientific literature published between July 2021 and July 2023, which analyzes all reports of inflammatory signatures of serious adverse effects caused by COVID-19 vaccines.
ResultsThe systematic review identified 2033 records which, after a screening process according to the inclusion criteria and the elimination of duplicated papers, works with methodological problems and works without open access, were reduced to 58 articles, of which 50 articles are human models and 2 are cellular models.
ConclusionThe results of this systematic review reveal the causal and temporal association of the various serious adverse events following administration of COVID-19 vaccines and the “peak effect” of COVID-19 vaccines is recognized.
Keywords:
COVID-19 Vaccine
Adverse events
SARS-CoV-2 Vaccine
Artículo
Opciones para acceder a los textos completos de la publicación Vacunas
Suscriptor
Comprar
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Bibliografía
[1]
D.S. Mouliou, E. Dardiotis.
Current evidence in SARS-CoV-2 mRNA vaccines and post-vaccination adverse reports: knowns and unknowns.
Diagnostics (Basel) [Internet], 12 (2022), pp. 1555
[2]
A. Nagy, B. Alhatlani.
An overview of current COVID-19 vaccine platforms.
Comput Struct Biotechnol J [Internet], 19 (2021), pp. 2508-2517
[3]
R. Verbeke, M.J. Hogan, K. Loré, N. Pardi.
Innate immune mechanisms of mRNA vaccines.
Immunity [Internet], 55 (2022), pp. 1993-2005
[4]
K. Karikó, M. Buckstein, H. Ni, D. Weissman.
Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA.
Immunity [Internet], 23 (2005), pp. 165-175
[5]
P.R. Cullis, M.J. Hope.
Lipid nanoparticle systems for enabling gene therapies.
Mol Ther [Internet], 25 (2017), pp. 1467-1475
[6]
F.P. Polack, S.J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, et al.
Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine.
N Engl J Med [Internet], 383 (2020), pp. 2603-2615
[7]
E.J. Wherry, D.H. Barouch.
T cell immunity to COVID-19 vaccines.
Forensic Sci Int, 377 (2022), pp. 821-822
[8]
A. Sette, S. Crotty.
Adaptive immunity to SARS-CoV-2 and COVID-19.
Cell [Internet], 184 (2021), pp. 861-880
[9]
M.G. Alameh, D. Weissman.
Nucleoside modifications of in vitro transcribed mRNA to reduce immunogenicity and improve translation of prophylactic and therapeutic antigens.
RNA Therapeutics [Internet], (2022), pp. 141-169
[10]
R. Verbeke, I. Lentacker, S.C. De Smedt, H. Dewitte.
Three decades of messenger RNA vaccine development.
NANO TODAY [Internet], (2019), pp. 28
[11]
J. Lutz, S. Lazzaro, M. Habbeddine, K.E. Schmidt, P. Baumhof, B.L. Mui, et al.
Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines.
NPJ Vaccines [Internet], 2 (2017), pp. 29
[12]
B.R. Anderson, H. Muramatsu, S.R. Nallagatla, P.C. Bevilacqua, L.H. Sansing, D. Weissman, et al.
Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation.
Nucleic Acids Res [Internet], 38 (2010), pp. 5884-5892
[13]
B.R. Anderson, H. Muramatsu, B.K. Jha, R.H. Silverman, D. Weissman, K. Karikó.
Nucleoside modifications in RNA limit activation of 2´- 5´- oligoadenylate synthetase and increase resistance to cleavage by RNase L.
Nucleic Acids Res [Internet], 39 (2011), pp. 9329-9338
[14]
K.J. Hasset, K.E. Benenato, E. Jacquinet, A. Lee, A. Woods, O. Yuzhakov, et al.
Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines.
Mol Ther Nucleic Acids [Internet], 15 (2019), pp. 1-11
[15]
J. Szebeni, G. Storm, J.Y. Ljubimova, M. Castells, E.J. Phillips, K. Turjeman, et al.
Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA- based SARS-CoV-2 vaccines.
Nat Nanotechnol [Internet], 17 (2022), pp. 337-346
[16]
M.G. Alameh, I. Tombácz, E. Bettini, K. Lederer, C. Sittplangkoon, J.R. Wilmore, et al.
Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T folicular helper cell and humoral responses.
Immunity [Internet], 54 (2021),
[17]
L.R. Baden, H.M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, et al.
Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.
N Engl J Med [Internet], 384 (2021), pp. 403-416
[18]
G. Graziani, P.M. Lacal.
Neuropilin-1 as therapeutic target for malignant melanoma.
Front Oncol [Internet], 5 (2015), pp. 125
[19]
P. Comstedt, M. Stogaard, A.T. Lassen.
The systemic inflammatory response syndrome (SIRS) in acutely hospitalised medical patients: a cohort study.
Scand J Trauma, Resusc Emerg Med [Internet], 17 (2009), pp. 67
[20]
A. Morsi, E. Mersal, A. Hassanein, A. Alshammri, A. Alshammri, N. Alkahmous, et al.
The association between COVID-19 Pfizer vaccine and the reported post-vaccination menstrual changes in citizen and resident women in KSA: results of Riyadh Survey Study.
The Egyptian Journal of Hospital Medicine [Internet], 87 (2022), pp. 1442-1448
[21]
L. Trogstad, I. Laake, A.H. Robertson, S. Mjaaland, I.H. Caspersen, L.K. Juvet, et al.
Heavy Bleeding and other menstrual disturbances in young women after COVID-19 vaccination.
Vaccine [Internet], (2023),
[22]
M.M. Morikawa, M. Harada, E. Kishimoto, K. Suzuki, E. Nakagawa, T. Hiramatsu, et al.
BNT162b2 coronavirus disease-2019 vaccination accelerated rheumatoid arthritis disease activity in chronic eosinophilic pneumonia: a case report.
Medicine (Baltimore) [Internet], 101 (2022),
[23]
T. Namiki, S. Komine-Aizawa, K. Takada, C. Takano, Q.D. Trinh, S. Hayakawa.
The association of three doses of the BNT162b2 mRNA vaccine with abnormal bleeding and an irregular menstrual cycle among premenopausal females: a single institute observation study.
J Obstet Gynaecol Res [Internet], 48 (2022), pp. 2903-2910
[24]
N. Zagorec, I. Horvatic, P. Senjug, M. Horacek, D. Galesic Ljubanovic, K. Galesic.
Immune-mediated diseases after coronavirus disease 2019 vaccination: rare but important complication.
Croat Med J [Internet], 63 (2022), pp. 389-393
[25]
I. Levy, E.G. Levin, L. Olmer, G. Regev-Yochay, N. Agmon-Levin, A. Wieder-Finesod, et al.
Correlation between adverse events and antibody titers among healthcare workers vaccinated with BNT162b2 mRNA COVID-19 vaccine.
Vaccines (Basel) [Internet], 10 (2022), pp. 1220
[26]
A. Piras, G. Melis, L. Cugusi, P.P. Bassareo.
Myopericarditis in a male adolescent following the second shot of COVID-19 Pfizer m-RNA vaccine: typical example and analysis of 110 single case reports.
Pediatr Rep [Internet], 14 (2022), pp. 401-409
[27]
H. Abu Serhan, A. Abdelaal, M.T. Abuawwad, M.J.J. Taha, S. Irshaidat, L. Abu Serhan, et al.
Ocular vascular events following COVID-19 vaccines: a systematic review.
Vaccines (Basel) [Internet], 10 (2022), pp. 2143
[28]
Z. Mohseni Afshar, A. Sharma, A. Babazadeh, A. Alizadeh-Khatir, T.T. Sio, M.A. Taghizadeh Moghadam, et al.
A review of the potential neurological adverse events of COVID-19 vaccines.
Acta Neurol Belg [Internet], 123 (2023), pp. 9-44
[29]
H.J. Lee, Y.J. Jeong, Y.J. Kim, S.H. Kim.
Multisystem inflammatory syndrome in an adult following COVID-19 mRNA vaccination: successful treatment with medium-dose steroids and colchicine.
J Korean Med Sci [Internet], 37 (2022),
[30]
C.C. Chen, C.K. Chang, C.C. Chiu, T.Y. Yang, W.R. Hao, C.H. Lin, et al.
Machine learning analyses revealed distinct arterial pulse variability according to side effects of Pfizer-BioNTech COVID-19 vaccine (BNT162b2).
J Clin Med [Internet], 11 (2022), pp. 6119
[31]
C. Hoffmann, T. Wechselberger, H. Drexel, S. Dertinger, S. Dimhofer, S.K. Pierson, et al.
Idiopathic multicentric castleman disease occurring shortly after mRNA SARS-CoV-2 vaccine.
Vaccines (Basel) [Internet], 10 (2022), pp. 1725
[32]
K.K. Wong, C.M. Heilig, A. Hause, T.R. Myers, C.K. Olson, J. Gee, et al.
Menstrual irregularities and vaginal bleeding after COVID-19 vaccination reported to v-safe active surveillance, USA in December, 2020-January, 2022: an observational cohort study.
Lancet Digit Health [Internet], 4 (2022), pp. e667-e675
[33]
J.E. Kim, J. Park, T.J. Song.
A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database.
Mult Scler Int, 28 (2022), pp. 2112-2123
[34]
A.A. Tamborska, B. Singh, S.E. Leonhard, E.M. Hodel, J. Stowe, T. Watson-Fargie, et al.
Guillain-Barré syndrome following SARS-CoV-2 vaccination in the UK: a prospective surveillance study.
BMJ Neurol Open [Internet], 4 (2022),
[35]
E. Magen, S. Mukherjee, M. Bhattacharya, R. Detroja, E. Merzon, I. Blum, et al.
Clinical and molecular characterization of a rare case of BNT162b2 mRNA covid-19 vaccine-associated myositis.
Vaccines (Basel) [Internet], 10 (2022), pp. 1135
[36]
D. Pisani, F.M. Gioacchini, P. Viola, A. Scarpa, A. Astorina, M. Re, et al.
Audiovestibular disorders after COVID-19 vaccine: is there an association?.
Audiol Res [Internet], 12 (2022), pp. 212-223
[37]
P. Ekobena, L.E. Rothuizen, F. Bedussi, P. Guilcher, S. Meylan, A. Ceschi, et al.
Four cases of audio-vestibular disorders related to immunisation with SARS-CoV-2 mRNA vaccines.
Int J Audiol [Internet], 62 (2022), pp. 587-591
[38]
I. Caliskan, E. Bulus, N. Afsar, A. Altintas.
A case with new-onset neuromyelitis optica spectrum disorder following COVID-19 mRNA BNT162b2 vaccination.
Neurologist [Internet], 27 (2022), pp. 147-150
[39]
M.M. Aliasin, N. Yazdanpanah, N. Rezaei.
Neurological and neuropsychological adverse effects of SARS-CoV-2 vaccines – where do we stand?.
Rev Neurosci [Internet], 33 (2022), pp. 721-743
[40]
E. Azzolini, L.M. Canziani, A. Voza, A. Desai, J. Pepys, M. De Santis, et al.
Short-term adverse events and antibody response to the BNT162b2 SARS-CoV-2 vaccine in 4156 health care professionals.
Vaccines (Basel) [Internet], 10 (2022), pp. 439
[41]
S.H. Ahmed, S. Waseem, T.G. Shaikh, N.A. Qadir, S.A. Siddiqui, I. Ullah, et al.
SARS-CoV-2 vaccine-associated-tinnitus: a review.
Ann Med Surg (Lond) [Internet], 75 (2022),
[42]
C.S. Son, S.H. Jin, W.S. Kang.
Propensity-score-matched evaluation of adverse events affecting recovery after COVID-19 vaccination: on adenovirus and mRNA vaccines.
Vaccines (Basel) [Internet], 10 (2022), pp. 284
[43]
Y.K. Kim, D. Minn, S.H. Chang, J.S. Suh.
Comparing SARS-CoV-2 antibody responses after various COVID-19 vaccinations in healthcare workers.
Vaccines [Internet], 10 (2022), pp. 193
[44]
J. Finsterer, F.A. Scorza, C.A. Scorza.
Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients.
Clinics (Sao Paulo) [Internet], 76 (2021),
[45]
S. Umezawa, K. Ioka, S. Aizawa, Y. Tashiro, K. Yoshizawa.
First manifestation of AQP4-IgG-positive neuromyelitis optica spectrum disorder following the COVID-19 mRNA vaccine BNT162b2.
Neurol Sci [Internet], 44 (2023), pp. 451-455
[46]
G. Hetland, M.K. Fagerhol, M.K.H. Wiedmann, A.V.L. Søraas, M.R. Mirlashari, L.S.H. Nissen-Meyer, et al.
Elevated NETs and calprotectin levels after ChAdOx1 nCoV-19 vaccination correlate with the severity of side effects.
Vaccines [Internet], 10 (2022), pp. 1267
[47]
M.E. Mingot-Castellano, N. Butta, M. Canaro, Gómez Del Castillo, M.C.D. Solano, B. Sánchez-González, R. Jiménez-Bárcenas, et al.
COVID-19 vaccines and autoimmune hematologic disorders.
Vaccines (Basel) [Internet], 10 (2022), pp. 961
[48]
H. Watanabe, M. Ashida, N. Satomi, Y. Koike, S. Kuwatsuka, H. Murota.
Histopathological analysis of skin reactions after coronavirus disease 2019 vaccination: increment in number of infiltrated plasmacytoid dentritic cell.
J Dermatol [Internet], 49 (2022), pp. 732-735
[49]
S. Abbasi, A. Alsermani, A. Alsegayyir, T. Altahan, M. Alsermani, S. Almustanyir.
Vaccine-induced thrombotic thrombocytopenia: a case of splanchnic veins thrombosis.
Cureus [Internet], 14 (2022),
[50]
B.T. Chow, C.K. Lai.
Lymphohistiocytic myocarditis possibly due to Moderna mRNA-1273 vaccine.
Am J Clin Pathol [Internet], 158 (2022), pp. 167-172
[51]
Y. Zlotnik, A. Gadoth, I. Abu-Salameh, A. Horev, R. Novoa, G. Ifergane.
Case report: anti-LGI1 encephalitis following COVID-19 vaccination.
Front Immunol [Internet], 12 (2022),
[52]
R. Ameratunga, S.T. Woon, M.N. Sheppard, J. Garland, B. Ondruschkla, C.X. Wong, et al.
First identified case of fatal fulminant necrotizing eosinophilic myocarditis following the initial dose of the Pfizer-BioNTech mRNA COVID-19 vaccine (BNT162b2, Comirnaty): an extremely rare idiosyncratic hypersensitivity reaction.
J Clin Immunol [Internet], 42 (2022), pp. 441-447
[53]
J.W. Duijster, M.E. Schoep, B.T.E. Nieboer, R. Jajou, A. Kant, F. van Hunsel.
Menstrual abnormalities after COVID-19 vaccination in the Netherlands: a description of spontaneous and longitudinal patient-reported data.
Br J Clin Pharmacol [Internet], (2023),
[54]
C. Li, A. Lee, L. Grigoryan, P.S. Arunachalam, M.K.D. Scott, M. Trisal, et al.
Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine.
Nat Immunol [Internet], 23 (2022), pp. 543-555
[55]
S. Tahtinen, A.J. Tong, P. Himmels, J. Oh, A. Paler-Martinez, L. Kim, et al.
IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines.
Nat Immunol [Internet], 23 (2022), pp. 532-542
[56]
S. Ndeupen, Z. Qin, S. Jacobsen, A. Bouteau, H. Estanbouli, B.Z. Igyártó.
The mRNA-LNP platform´s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory.
iScience [Internet], 24 (2021),
[57]
A.J. Plant-Hately, B. Eryilmaz, C.A.W. David, D.E. Brain, B.J. Heaton, Y. Perrie, et al.
Exposure of the basophilic cell line KU812 to liposomes reveals activation profiles associated with potential anaphylactic responses linked to physico-chemical characteristics.
Pharmaceutics [Internet], 14 (2022), pp. 2470
[58]
F.M. Fisher, E. Maratos-Flier.
Understanding the physiology of FGF21.
Annu Rev Physiol [Internet], 78 (2016), pp. 223-241
[59]
M. Aldén, F. Olofsson Falla, D. Yang, M. Barghouth, C. Luan, M. Rasmussen, et al.
Intracellular reverse transcription of Pfizer BioNTech COVID-19 mRNA vaccine BNT162b2 In vitro in human liver cell line.
Curr Issues Mol Biol [Internet], 44 (2022), pp. 1115-1126
[60]
Q. Li, Y. Wang, Q. Sun, J. Knopf, M. Herrmann, L. Lin, et al.
Immune response in COVID-19: what is next?.
Cell Death Differ [Internet], 29 (2022), pp. 1107-1122
[61]
U. Elia, S. Ramishetti, R. Rosenfeld, N. Dammes, E. Bar-Haim, G.S. Naidu, et al.
Design of SARS-CoV-2 hFc-conjugated receptor-binding domain mRNA vaccine delivered via lipid nanoparticles.
ACS Nano [Internet], 15 (2021), pp. 9627-9637
[62]
M.J. Carrasco, S. Alishetty, M.G. Alameh, H. Said, L. Wright, M. Paige, et al.
Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration.
Commun Biol [Internet], 4 (2021), pp. 956
[63]
K. Röltgen, S.C.A. Nielsen, O. Silva, S.F. Younes, M. Zaslavsky, C. Costales, et al.
Immune imprinting, breadth of variant recognition, and germinal centre response in human SARS-CoV-2 infection and vaccination.
Cell [Internet], 185 (2022),
[64]
H.H. Tam, M.B. Melo, M. Kang, J.M. Pelet, V.M. Ruda, M.H. Foley, et al.
Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination.
Proc Natl Acad Sci U S A [Internet], 113 (2016), pp. E6639-E6648
[65]
N. Pardi, M.J. Hogan, M.S. Naradikian, K. Parkhouse, D.W. Cain, L. Jones, et al.
Nucleoside-modified mRNA vaccines induce potent T folicular helper and germinal center B cell responses.
J Exp Med [Internet], 215 (2018), pp. 1571-1588
[66]
K. Röltgen, S.C.A. Nielsen, O. Silva, S.F. Younes, M. Zaslavsky, C. Costales, et al.
Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination.
Cell [Internet], 185 (2022),
[67]
G. Guerrera, M. Picozza, S. D’Orso, R. Placido, M. Pirronello, A. Verdiani, et al.
BNT162b2 vaccination induces durable SARS-CoV-2-specific T Cells whith a stem cell memory phenotype.
Sci Immunol [Internet], 6 (2021),
[68]
Z. Zhang, U. Ohto, T. Shibata, E. Krayukhina, M. Taoka, Y. Yamauchi, et al.
Structural analysis reveals that toll-like receptor 7 is a dual receptor for guanosine and single-stranded RNA.
Immunity [Internet], 45 (2016), pp. 737-748
[69]
M.M. Painter, D. Mathew, R.R. Goel, S.A. Apostolidis, A. Pattekar, O. Kuthuru, et al.
Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and celular immunity to SARS-CoV-2 mRNA vaccination.
Immunity [Internet], 54 (2021),
[70]
V. Oberhardt, H. Luxenburger, J. Kemming, I. Schulien, K. Ciminski, S. Giese, et al.
Rapid and stable mobilization of CD8+ T Cells by SARS-CoV-2 mRNA vaccine.
Nature [Internet], 597 (2021), pp. 268-273
[71]
J.S. Turner, J.A. O’Halloran, E. Kalaidina, W. Kim, A.J. Schmitz, J.Q. Zhou, et al.
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses.
Nature [Internet], 596 (2021), pp. 109-113
[72]
S.A. Dilliard, Q. Cheng, D.J. Siegwart.
On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles.
Proc Natl Acad Sci U S A [Internet], 118 (2021),
[73]
V. Francia, R.M. Schiffelers, P.R. Cullis, D. Witzigmann.
The biomolecular corona of lipid nanoparticles for gene therapy.
Bioconjug Chem [Internet], 31 (2020), pp. 2046-2059
[74]
A. Six, B. Bellier, V. Thomas-Vaslin, D. Klatzmann.
Systems biology in vaccine design.
Microb Biotechnol [Internet], 5 (2012), pp. 295-304
[75]
F. Liang, G. Lindgren, A. Lin, E.A. Thompson, S. Ols, J. Röhss, et al.
Efficient Targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques.
Mol Ther [Internet], 25 (2017), pp. 2635-2647
[76]
S. Ndeupen, A. Bouteau, C. Herbst, Z. Qin, S. Jacobsen, N.E. Powers, et al.
Langerhans cells and cDC1s play redundant roles in mRNA-LNP induced protective anti-influenza and anti-SARS-CoV-2 immune responses.
PLoS Pathog [Internet], 18 (2022),
[77]
H. Tanji, U. Ohto, T. Shibata, M. Taoka, Y. Yamauchi, T. Isobe, et al.
Toll-like receptor 8 senses degradation products of single-stranded RNA.
Nat Struct Mol Biol [Internet], 22 (2015), pp. 109-115
[78]
H. Mitoma, S. Hanabuchi, T. Kim, M. Bao, Z. Zhang, N. Sugimoto, et al.
The DHX33 RNA helicase senses cytosolic RNA and activates the NLRP3 inflammasome.
Immunity [Internet], 39 (2013), pp. 123-135
[79]
M. Yoneyama, M. Kikuchi, K. Matsumoto, T. Imaizumi, M. Miyagishi, K. Taira, et al.
Shared and unique functions of the DExD/H-box helicases RIG-1, MDA5, and LGP2 in antiviral innate immunity.
J Immunol [Internet], 175 (2005), pp. 2851-2858
[80]
M. Yoneyama, M. Kikuchi, T. Natsukawa, N. Shinobu, T. Imaizumi, M. Miyagishi, et al.
The RNA helicase RIG-1 has an essential function in double-stranded RNA-induced innate antiviral responses.
Nat Immunol [Internet], 5 (2004), pp. 730-737
[81]
Y.M. Abbas, B.T. Laudenbach, S. Martinez-Montero, R. Cencic, M. Habjan, A. Pilchlmair, et al.
Structure of human IFIT1 with capped RNA reveals adaptable mRNA binding and mechanisms for sensing N1 and N2 ribosome 2`-O methylations.
Proc Natl Acad Sci U S A [Internet], 114 (2017), pp. E2106-E2115
[82]
S.C. Devarkar, C. Wang, M.T. Miller, A. Ramanathan, F. Jiang, A.G. Khan, et al.
Structural basis for m7G recognition and 2´-O methyl discrimination in capped RNAs by the innate immune receptor RIG-1.
Proc Natl Acad Sci U S A [Internet], 113 (2016), pp. 596-601
[83]
C. Schuberth-Wagner, J. Ludwig, A.K. Bruder, A.M. Herzner, T. Zillinger, M. Goldeck, et al.
A conserved histidine in the RNA sensor RIG-1 controls immune tolerance to N1-2´O-methylated self RNA.
Immunity [Internet], 43 (2015), pp. 41-51
[84]
K. Lenart, F. Hellgren, S. Ols, X. Yan, A. Cagigi, R.A. Cerveira, et al.
A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses.
Mol Ther Methods Clin Dev [Internet], 27 (2022), pp. 309-323
[85]
X. Mu, E. Greenwald, S. Ahmad, S. Hur.
An origin of the immunogenicity of in vitro transcribed RNA.
Nucleic Acids Research [Internet], 46 (2018), pp. 5239-5249
[86]
A.F. Durbin, C. Wang, J. Marcotrigiano, L. Gehrke.
RNAs containing modified nucleotides fail to trigger RIG-1 conformational changes for innate immune signaling.
mBio [Internet], 7 (2016), pp. e00816-e00833
[87]
P.S. Arunachalam, M.K.D. Scott, T. Hagan, C. Li, Y. Feng, F. Wimmers.
Systems vaccinology of the BNT162b2 mRNA vaccine in humans.
Nature [Internet], 596 (2021), pp. 410-416
[88]
J. Chapin-Bardales, J. Gee, T. Myers.
Reactogenicity following receipt of mRNA-based COVID-19 vaccines.
JAMA [Internet], 325 (2021), pp. 2201-2202
[89]
H.G. Rosenblum, J. Gee, R. Liu, P.L. Marquez, B. Zhang, P. Strid, et al.
Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the vaccine adverse events reporting system and v-safe.
Lancet Infect Dis [Internet], 22 (2022), pp. 802-812
[90]
K. Kobiyama, K.J. Ishii.
Macking innate sense of mRNA vaccine adjuvanticity.
Nat Immunol [Internet], 23 (2022), pp. 474-476
[91]
S.D. Liu, L.P. Zhong, J. He, Y.X. Zhao.
Targeting neuropilin-1 interactions is a promising anti-tumor strategy.
Chin Med J (Engl) [Internet], 134 (2021), pp. 508-517
[92]
M. Ackerman, D. Henry, A. Finon, R. Binois, E. Esteve.
Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccines.
J Eur Acad Dermatol Venereol [Internet], 35 (2021), pp. e423-e425
[93]
D. Weismann, C.J. Binder.
The innate immune response to products of phospholipid peroxidation.
Biochim Biophys Acta [Internet], 1818 (2012), pp. 2465-2475
[94]
L. Miao, L. Li, Y. Huang, D. Delcassian, J. Chahal, J. Han, et al.
Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation.
Nat Biotechnol [Internet], 37 (2019), pp. 1174-1185
[95]
T. Tanaka, A. Legat, E. Adam, J. Steuve, J.S. Gadot, M. Vandenbraden, et al.
DiC14-amidine cationic liposomes stimulate myeloid dendritic cells through toll-like receptor 4.
Eur J Immunol [Internet], 38 (2008), pp. 1351-1357
[96]
C. Lopez, M. Bessodes, D. Scherman, M. Vandenbranden, V. Escriou, J.M. Ruysschaert.
Cationic lipid nanocarriers activate toll-like receptor 2 and NLRP3 inflammasome pathways.
Nanomedicine [Internet], 10 (2014), pp. 775-782
[97]
A. Pichlmair, O. Schulz, C.P. Tan, J. Rehwinkel, H. Kato, O. Takeuchi, et al.
Activation of MDA5 requires higher-order RNA structures generated during virus infection.
J Virol [Internet], 83 (2009), pp. 10761-10769
[98]
A. Edelman, E.R. Boniface, E. Benhar, L. Han, K.A. Matteson, C. Favaro, et al.
Association between menstrual cycle length and coronavirus disease 2019 (COVID-19) vaccination: a U.S. cohort.
Obstet Gynecol [Internet], 139 (2022), pp. 481-489
[99]
C.K. Holm, S.B. Jensen, M.R. Jakobsen, N. Cheshenko, K.A. Horan, H.B. Moeller, et al.
Virus-cell fusion as a trigger of innate immnunity dependent on the adaptor STING.
Nat Immunol [Internet], 13 (2012), pp. 737-743
[100]
L. Besedovsky, T. Lange, M. Haack.
The sleep-immune crosstalk in health and disease.
Physiol Rev [Internet], 99 (2019), pp. 1325-1380
[101]
J.A. Whitaker, I.G. Ovsyannnikova, G.A. Poland.
Adversomics: a new paradigm for vaccine safety and design.
Expert Rev Vaccines [Internet], 14 (2015), pp. 935-947
[102]
K. Murata, N. Nakao, N. Ishiuchi, T. Fukui, N. Katsuya, W. Fukumoto, et al.
Four cases of cytokine storm after COVID-19 vaccination: case report.
Front Immunol [Internet], 13 (2022),
[103]
A. Alvergne, G. Kountourides, M.A. Argentieri, L. Agyen, N. Rogers, D. Knight, et al.
COVID-19 vaccination and menstrual cycle changes: a United Kingdom (UK) retrospective case-control study.
medRxiv [Internet], 11 (2021), pp. 21266709
[104]
C. Chen, F. Fu, L. Ding, J. Xiao.
Hearing disorder following COVID-19 vaccination: a pharmacovigilance analysis using the vaccine adverse event reporting system.
J Clin Pharm Ther [Internet], 47 (2022), pp. 1789-1795
[105]
T. Lagousi, I. Papadatou, P. Strempas, E. Chatzikalil, V. Spoulou.
Paving the way towards precision vaccinology: the paradigm of myocarditis after coronavirus disease 2019 (COVID-19) vaccination.
Clin Infect Dis [Internet], 75 (2022), pp. S18-S23
[106]
V. Pirani, P. Pelliccioni, M.J. Carpenè, M. Nicolai, F. Barbotti, A. Franceschi, et al.
Optic neuritis following COVID-19 vaccination: do autoimmune diseases play a role?.
Eur J Ophthamol [Internet], 33 (2022),
[107]
R. Tallota.
Impaired VEGF-A mediated neurovascular crosstalk induced by SARS-CoV-2 spike protein: a potential hypothesis explaining long COVID-19 symptoms and COVID-19 vaccine side effects?.
Microorganisms [Internet], 10 (2022), pp. 2452
[108]
K.P. Ivengar, V.K. Jain, R. Vaishya, P. Ish.
Long COVID-19: an emerging pandemic in itself.
Adv Respir Med [Internet], 89 (2021), pp. 234-236
[109]
I.P. Trougakos, K. Stamatelopoupos, E. Terpos, O.E. Tsitilonis, E. Aivalioti, D. Paraskevis, et al.
Insights to SARS-CoV-2 life cycle, pathophysiology and rationalized treatments that target COVID-19 clinical complications.
J Biomed Sci [Internet], 28 (2021), pp. 9
[110]
F. Angeli, G. Reboldi, M. Trapasso, M. Zappa, A. Spanevello, P. Verdecchia.
COVID-19, vaccines and deficiency of ACE2 and other angiotensinases. Closing the loop on the “Spike effect”.
Eur J Intern Med [Internet], 103 (2022), pp. 23-28
[111]
M. Federico.
Biological and immune responses to current anti-SARS-CoV-2 mRNA vaccines beyond anti-spike antibody production.
J Immunol Res [Internet], 2022 (2022), pp. 4028577
[112]
European Medicines Agency (EMA). Science Medicines Health. [Internet].
Assessment history.
[113]
A.V. Turnbull, C.L. Rivier.
Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action.
Physiol Rev [Internet], 79 (1999), pp. 1-71
[114]
CASPE [Internet].
Programa de habilidades en lectura crítica Español.
(2022)http://www.redcaspe.org/
[115]
M. Yoshida, Y. Kobashi, Y. Shimazu, H. Saito, C. Yamamoto, T. Kawamura, et al.
Time course of adverse reactions following BNT162b2 vaccination in healthy and allergic disease individuals aged 5-11 years and comparison with individuals aged 12-15 years: an observational and historical cohort study.
Eur J Pediatr [Internet], 182 (2023), pp. 123-133
[116]
J.M. Granados Villalpando, SdJ Romero Tapia, GdC Baeza Flores, J.L. Ble Castillo, I.E. Juarez Rojop, F.I. Lopez Junco, et al.
Prevalence and risk factors of adverse effects and allergic reactions after COVID-19 vaccines in a Mexican population: an analytical cross-sectional study.
Vaccines [Internet], 10 (2022), pp. 2012
[117]
L. Martínez Muñoz, R. Barroso, S.Y. Dyrhaug, G. Navarro, P. Lucas, S.F. Soriano, et al.
CCR5/CD4/CXCR4 oligomerization prevents HIV-1 gp120IIIB binding to the cell surface.
Proc Natl Acad Sci U S A [Internet], 111 (2014), pp. E1960-E1969
[118]
W.R. Burns, Y. Wang, P.C. Tang, H. Ranjbaran, A. Iakimov, J. Kim, et al.
Recruitment of CXCR3+ and CCR5+ T cells and production of interferon-γ-inducible chemokines in rejecting human arteries.
Am J Transplant [Internet], 5 (2005), pp. 1226-1236
[119]
P. Isaikina, C.J. Tsai, N. Dietz, F. Pamula, A. Grahl, K.N. Goldie, et al.
Structural basis of the activation of the CC chemokine receptor 5 by a chemokine agonist.
Sci Adv [Internet], 7 (2021),
[120]
Y. Chen, Y. Li, T. Zhan.
A case report of possible concurrent vasculitis in vertebral bodies and partial transverse myelitis following COVID-19 vaccination.
Medicine (Baltimore) [Internet], 101 (2022),
[121]
F. Angelini, A. Spanevello, G. Reboldi, D. Visca, P. Verdecchia.
SARS-CoV-2 vaccines: lights and shadows.
Eur J Intern Med [Internet], 88 (2021), pp. 1-8
[122]
G. Schuch, M. Machluf, G. Bartsch Jr., M. Nomi, H. Richard, A. Atala, et al.
In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo.
Blood [Internet], 100 (2002), pp. 4622-4628
[123]
F. Ruffini, S. D’Atri, P.M. Lacal.
Neuropilin-1 expression promotes invasiveness of melanoma cells through vascular endothelial growth factor receptor-2-dependent and independent mechanisms.
Int J Oncol [Internet], 43 (2013), pp. 297-306
[124]
S. Roy, A.K. Bag, R.K. Singh, J.E. Talmadge, S.K. Batra, K. Datta.
Multifaceted role of neuropilins in the immune system: potential targets for immunotherapy.
Front Immunol [Internet], 8 (2017), pp. 1228
[125]
L. Zhao, H. Chen, L. Lu, L. Wang, X. Zhang, X. Guo.
New insights into the role of co-receptor neuropilins in tumour angiogenesis and lymphangiogenesis and targeted therapy strategies.
J Drug Target [Internet], 29 (2021), pp. 155-167
[126]
J. Wang, Y. Huang, J. Zhang, B. Xing, W. Xuan, H. Wang, et al.
NRP-2 in tumor lymphangiogenesis and lymphatic metastasis.
Cancer Lett [Internet], 418 (2018), pp. 176-184
[127]
M. Shibuya.
Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis.
Angiogenesis [Internet], 9 (2006), pp. 225-231
[128]
C. Hu, X. Jiang.
Role of NRP-1 in VEGF-VEGFR2-independent tumorigenesis.
Target Oncol [Internet], 11 (2016), pp. 501-505
[129]
G.A. Secker, N.L. Harvey.
Regulation of VEGFR signalling in lymphatic vascular development and disease: an update.
Int J Mol Sci [Internet], 22 (2021), pp. 7760
[130]
S. Schellenburg, A. Schulz, D.M. Poitz, M.H. Muders.
Role of neuropilin-2 in the immune system.
Mol Immunol [Internet], 90 (2017), pp. 239-244
[131]
A. Trigunaite, J. Dimo, T.N. Jørgensen.
Suppresive effects of androgens on the immune system.
Cell Immunol [Internet], 294 (2015), pp. 87-94
[132]
F. Chen, P. Cao, H. Liu, D. Cai.
The impact of COVID-19 and vaccine on the human nervous system.
Neuroendocrinology [Internet], 112 (2022), pp. 1046-1057
[133]
B.B. Garrido-Suárez, M. Garrido-Valdes, G. Garrido.
Reactogenic sleepiness after COVID-19 vaccination. A hypothesis involving orexinergic system linked to inflammatory signals.
Sleep Med [Internet], 98 (2022), pp. 79-86
[134]
X. Kang, H. Tang, Y. Liu, Y. Yuan, M. Wang.
Research progress on the mechanism of orexin in pain regulation in different brain regions.
Open Life Sci [Internet], 16 (2021), pp. 46-52
[135]
J.L. Bueno, M. Ynigo, C. de Miguel, R.M. Gonzalo-Daganzo, A. Richart, C. Vilches, et al.
Growth differentation factor 11 (GDF11) - a promising anti-ageing factor - is highly concentrated in platelets.
Vox Sang [Internet], 111 (2016), pp. 434-436
[136]
M.A. Egerman, S.M. Cadena, J.A. Gilbert, A. Meyer, H.N. Nelson, S.E. Swalley, et al.
GDF11 increases with age and inhibits skeletal muscle regeneration.
Cell Metab [Internet], 22 (2015), pp. 164-174
[137]
G.M. Leinninger, D.M. Opland, Y.H. Jo, M. Faouzi, L. Christensen, L.A. Cappellucci, et al.
Leptin action via neurotensin neurons controls orexin, the mesolimbic dopamine system and energy balance.
Cell Metab [Internet], 14 (2011), pp. 313-323
[138]
A. Laque, S. Yu, E. Qualls-Creekmore, S. Gettys, C. Schwartzenburg, K. Bui, et al.
Leptin modulates nutrient reward via inhibitory galanin action on orexin neurons.
Mol Metab [Internet], 4 (2015), pp. 706-717
[139]
A.A. Ruiz Moré, L. González Méndez, E. Carvajal Ciomina, Fernández I. De Armas, J.R. Valdés Utrera, Parapar E. Machín.
Estimación de valores de referencia de la enzima mieloperoxidasa: biomarcador de deterioro clínico en pacientes con COVID-19.
Acta Méd Centro [Internet], 16 (2022), pp. 614-625
[140]
E. Bottino, A.A. Ponce.
Respuesta inmunitaria innata pulmonar en la infección por Sars-Cov-2.
Rev Fac Cien Med Univ Nac Cordoba [Internet], 79 (2022), pp. 33-42
[141]
J. Añón Hidalgo, V. Catalán, A. Rodríguez, B. Ramírez, A. Idoate- Bayón, C. Silva, et al.
Circulating concentrations of GDF11 are positively associated with TSH levels in humans.
J Clin Med [Internet], 8 (2019), pp. 878
[142]
S.C. Harper, A. Brack, S. MacDonnell, M. Franti, B.B. Olwin, B.A. Bailey, et al.
Is growth differentation factor 11 a realistic therapeutic for aging-dependent muscle defects?.
Circ Res [Internet], 118 (2016), pp. 1143-1150
[143]
M. Sinha, Y.C. Jang, J. Oh, D. Khong, E.Y. Wu, R. Manohar, et al.
Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle.
Forensic Sci Int, 344 (2014), pp. 649-652
[144]
D.W. Hammers, M. Merscham-Banda, J.Y. Hsiao, S. Engst, J.J. Hartman, H.L. Sweeney.
Supraphysiological levels of GDF11 induce striated muscle atrophy.
EMBO Mol Med [Internet], 9 (2017), pp. 531-544
[145]
K.A. Olson, A.L. Beatty, B. Heidecker, M.C. Regan, E.N. Brody, T. Foreman, et al.
Association of growth differentiation factor 11/8, putative anti-ageing factor, with cardiovascular outcomes and overall mortality in humans: analysis of the Heart and Soul and HUNT3 cohorts.
Eur Heart J [Internet], 36 (2015), pp. 3426-3434
[146]
S. Saini, S. Khurana, D. Saini, S. Rajput, C.J. Thakur, J. Singh, et al.
In silico analysis of genomic landscape of SARS-CoV-2 and its variant of concerns (Delta and Omicron) reveals changes in the coding potential of miRNAs and their target genes.
Gene [Internet], 853 (2023),
[147]
S.C. Ng, Y. Peng, L. Zhang, C.K. Mok, S. Zhao, A. Li, et al.
Gut microbiota composition is associated with SARS-CoV-2 vaccines immunogenicity and adverse events.
Gut [Internet], 71 (2022), pp. 1106-1116
[148]
A.M. Jamieson.
Influence of the microbiome on response to vaccination.
Hum Vaccin Immunother [Internet], 11 (2015), pp. 2329-2331
[149]
F. Sommer, F. Bäckhed.
The gut microbiota: masters of host development and physiology.
Nat Rev Microbiol [Internet], 11 (2013), pp. 227-238
[150]
A. Ciabattini, R. Olivieri, E. Lazzeri, D. Medaglini.
Role of the microbiota in the modulation of vaccine immune responses.
Front Microbiol [Internet], 10 (2019), pp. 1305
[151]
P. Zimmermann, N. Curtis.
The influence of the intestinal microbiome on vaccine responses.
Vaccine [Internet], 36 (2018), pp. 4433-4439
[152]
S. Rakoff-Nahoum, R. Medzhitov.
Regulation of spontaneus intestinal tumorigenesis through the adaptor protein MyD88.
Forensic Sci Int, 317 (2007), pp. 124-127
[153]
S. Lyoumi, F. Tamion, J. Petit, P. Déchelotte, C. Dauguet, M. Scotté, et al.
Induction and modulation of acute-phase response by protein malnutrition in rats: comparative effect of systemic and localized inflammation on interleukin-6 and acute-phase protein synthesis.
J Nutr [Internet], 128 (1998), pp. 166-174
[154]
K. Vlasakova, J. Bourque, W.J. Bailey, S. Patel, E.G. Besteman, R.J. Gonzalez, et al.
Universal accessible biomarkers of drug-induced tissue injury and systemic inflammation in rat: performance assessment of TIMP-1, A2M, AGP, NGAL and albumin.
Toxicol Sci [Internet], 187 (2022), pp. 219-233
[155]
U.P. Kodavanti, D. Andrews, M.C. Schladweiler, S.H. Gavett, D.E. Dodd, J.M. Cyphert.
Early and delayed effects of naturally occurring asbestos on serum biomarkers of inflammation and metabolism.
J Toxicol Environ Health A [Internet], 77 (2014), pp. 1024-1039
[156]
R. Hajjo, D.A. Sabbah, A. Tropsha.
Analyzing the systems iology effects of COVID-19 mRNA vaccines to assess their safety and putative side effects.
Pathogens [Internet], 11 (2022), pp. 743
[157]
S. Seneff, G. Nigh, A.M. Kyriakopoulos, P.A. McCullough.
Innate immune suppression by SARS-CoV-2 mRNA vaccinations: the role of G-quadruplexes, exosomes, and MicroRNAs.
Food Chem Toxicol [Internet], 164 (2022),
[158]
W. Tai, G. Zhao, S. Sun, Y. Guo, Y. Wang, X. Tao, et al.
A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.
Virology [Internet], 499 (2016), pp. 375-382
[159]
S.E. Oliver, J.W. Gargano, M. Marin, M. Wallace, K.G. Curran, M. Chamberland, et al.
The advisory committee on immunization practices interim recommendation for use of Moderna COVID-19 vaccine-United States, December 2020.
MMWR Morb Mortal Wkly Rep [Internet], 69 (2021), pp. 1653-1656
[160]
L. Buonaguro, B. Pulendran.
Immunogenomics and systems biology of vaccines.
Immunol Rev [Internet], 239 (2011), pp. 197-208
[161]
R. Ben-Othman, B. Cai, A.C. Liu, N. Varankovich, D. He, T.M. Blimkie, et al.
Systems biology methods applied to blood and tissue for a comprehensive analysis of immune response to hepatitis B vaccine in adults.
Front Immunol [Internet], 11 (2020),
[162]
T. Iba, J.H. Levy.
The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia.
Trends Cardiovasc Med [Internet], 32 (2022), pp. 1-9
[163]
S.H. Yun, E.H. Sim, R.Y. Goh, J.I. Park, J.Y. Han.
Platelet activation: the mechanisms and potential biomarkers.
Biomed Res Int [Internet], 2016 (2016), pp. 9060143
[164]
M.R. Yeaman.
Platelets: at the nexus of antimicrobial defence.
Nat Rev Microbiol [Internet], 12 (2014), pp. 426-437
[165]
H.D. Flad, E. Brandt.
Platelet-derived chemokines: pathophysiology and therapeutic aspects.
Cell Mol Life Sci [Internet], 67 (2010), pp. 2363-2386
[166]
E. Brandt, F. Petersen, A. Ludwig, J.E. Ehlert, L. Bock, H.D. Flad.
The β-thromboglobulins and platelet factor 4: blood platelet-derived CXC chemokines with divergent roles in early neutrophil regulation.
J Leukoc Biol [Internet], 67 (2000), pp. 471-478
[167]
J.D. McFadyen, H. Stevens, K. Peter.
The emerging threat of (micro) thrombosis in COVID-19 and its therapeutic implications.
Circ Res [Internet], 127 (2020), pp. 571-587
[168]
K. Martinod, C. Deppermann.
Immunothrombosis and thromboinflammation in host defense and disease.
Platelets [Internet], 32 (2021), pp. 314-324
[169]
A.K. Boehme, K. Doyle, K.T. Thakur, D. Roh, S. Park, S. Agarwal, et al.
Disorders of consciousness in hospitalized patients with COVID-19: the role of the systemic inflammatory response syndrome.
Neurocrit Care [Internet], 36 (2022), pp. 89-96
[170]
D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, PRISMA Group.
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
PLoS Med [Internet], 6 (2009),
[171]
C. Ittiwut, S. Mahasirimongkol, S. Srisont, R. Ittiwut, M. Chockjamsai, P. Durongkadech, et al.
Genetic basis of sudden death after COVID-19 vaccination in Thailand.
Heart Rhythm [Internet], 19 (2022), pp. 1874-1879
[172]
O.E. Çinar, B. Erdogdu, M. Karadeniz, S. Ünal, Ü.Y. Malkan, H. Göker, et al.
Hematologic malignancies diagnosed in the context of the mRNA COVID-19 vaccination campaign: a report of two cases.
Medicina (Kaunas) [Internet], 58 (2022), pp. 1575
[173]
M. Nazir, S. Asghar, M.A. Rathore, A. Shahzad, A. Shahid, A. Ashraf Khan, et al.
Menstrual abnormalities after COVID-19 vaccines: a systematic review.
Vacunas [Internet], 23 (2022), pp. S77-S87
[174]
A.S. Laganà, G. Veronesi, F. Ghezzi, M.M. Ferrario, A. Cromi, M. Bizzarri, et al.
Evaluation of menstrual irregularities after COVID-19 vaccination: results of the MECOVAC survey.
Open Med (Wars) [Internet], 17 (2022), pp. 475-484
[175]
N. Muhaidat, M.A. Alshrouf, M.I. Azzam, A.M. Karam, M.W. Al-Nazer, A. Al-Ani, et al.
Menstrual symptoms after COVID-19 vaccine: a cross-sectional investigation in the MENA region.
Int J Womens Health [Internet], 14 (2022), pp. 395-404
[176]
L. Monin, E.M. Whettlock, V. Male.
Immune responses in the human female reproductive tract.
Immunology [Internet], 160 (2020), pp. 106-115
[177]
A. Karagiannis, F. Harsoulis.
Gonodal dysfunction in systemic diseases.
Eur J Endocrinol [Internet], 152 (2005), pp. 501-513
[178]
J. Malik, A. Malik, M. Javaid, T. Zahid, U. Ishaq, M. Shoaib.
Thyroid function analysis in COVID-19: a retrospective study from a single center.
PLoS One [Internet], 16 (2021),
[179]
C. Perricone, F. Ceccarelli, G. Nesher, E. Borella, Q. Odeh, F. Conti, et al.
Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases.
Immunol Res [Internet], 60 (2014), pp. 226-235
[180]
N.I. Williams, S.L. Berga, J.L. Cameron.
Synergism between psychosocial and metabolic stressors: impact on reproductive function in cynomolgus monkeys.
Am J Physiol Endocrinol Metab [Internet], 293 (2007), pp. E270-E276
[181]
A. Barbarino, L. De Marinis, G. Folli, A. Tofani, S.D. Casa, C. D’Amico, et al.
Corticotropin-releasing hormone inhibition of gonadotropin secretion during the menstrual cycle.
Metabolism [Internet], 38 (1989), pp. 504-506
[182]
P.L. Moro, C.K. Olson, E. Clark, P. Marquez, P. Strid, S. Ellington, et al.
Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS).
Vaccine [Internet], 40 (2022), pp. 3389-3394
[183]
L. Monin, E.M. Whettlock, V. Male.
Immune responses in the human female reproductive tract.
Immunology [Internet], 160 (2020), pp. 106-115
[184]
CASPe.
Plantilla para ayudarte a entender una revisión sistemática. [Internet].
(2005), pp. 13-17
[185]
F. Rahimi Mansour, A. Keyvanfar, H. Najafiarab, S. Rajaei Firouzabadi, S. Sefidgar, S. Hooshmand Chayijan, et al.
Menstrual disturbances following COVID-19 vaccination: a probable puzzle about the role of endocrine and immune pathways.
J Reprod Immunol [Internet], 158 (2023),
[186]
B.K. Patterson, R. Yogendra, J. Guevara-Coto, R.A. Mora-Rodriguez, E. Osgood, J. Bream, et al.
Case series: maraviroc and pravastatin as a therapheutic option to treat long COVID/Post-acute sequelae of COVID (PASC).
Front Med (Lausanne) [Internet], 10 (2023), pp. 1122529
[187]
M.S. Green, V. Peer, A. Magid, N. Hagani, E. Anis, D. Nitzan.
Gender differences in adverse events following the Pfizer-BioNTech COVID-19 vaccine.
Vaccines (Basel) [Internet], 10 (2022), pp. 233
[188]
A.S. Lagana, G. Veronosi, F. Ghezzi, M.M. Ferrario, A. Cromi, M. Bizarri, et al.
Evaluation of menstrual irregularities after COVID-19 vaccination: results of the MECOVAC survey.
Open Med (Wars) [Internet], 17 (2022), pp. 475-484
[189]
V. Male.
Effect of COVID-19 vaccination on menstrual periods in a retrospectively recruited cohort.
MedRxiv [Internet], 11 (2021), pp. 21266317
[190]
R. Urakawa, E.T. Isomura, K. Matsunaga, K. Kubota.
Young age, female sex and no comorbidities are risk factors for adverse reactions after the third dose of BNT162b2 COVID-19 vaccine against SARS-COV-2: a prospective cohort study in Japan.
Vaccines (Basel) [Internet], 10 (2022), pp. 1357
[191]
E.P. Scully, J. Haverfield, R.L. Ursin, C. Tannenbaum, S.L. Klein.
Considering how biological sex impacts immune responses and COVID-19 outcomes.
Nat Rev Immunol [Internet], 20 (2020), pp. 442-447
[192]
I. Mohammad, I. Starskaia, T. Nagy, J. Guo, E. Yatkin, K. Väänänen, et al.
Estrogen receptor α contributes to T cell-mediated autoimmune inflammation by promoting T cell activation and proliferation.
Sci Signal [Internet], 11 (2018),
[193]
H. Jacobsen, S.L. Klein.
Sex differences in immunity to viral infections.
Front Immunol [Internet], 12 (2021),
[194]
M.R. Gubbels Bupp, T.N. Jorgensen.
Androgen-Induced Immunosuppression.
Front Immunol [Internet], 9 (2018), pp. 794
[195]
R.L. Ursin, J.R. Shapiro, S.L. Klein.
Sex-biased immune responses following SARS-CoV-2 infection.
Trends Microbiol [Internet], 28 (2020), pp. 952-954
[196]
U. Sahin, A. Muik, E. Derhovanessian, I. Vogler, L.M. Kranz, M. Vormehr, et al.
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cells responses.
Nature [Internet], 586 (2020), pp. 594-599
[197]
Coronavirus disease (COVID-19) [Internet]. COVID-19 vaccines.
[198]
NIH.
National Library of Medicine [Internet].
Medical Subjects Headings (MESH), (2023),
[199]
G. Urrútia, X. Bonfill.
Declaración PRISMA: una propuesta para mejorar la publicación de revisiones sistemáticas y metaanálisis.
Medicina Clínica [Internet], 135 (2010), pp. 507-511
[200]
B.J. Shea, J.M. Grimshaw, G.A. Wells, M. Boers, N. Andersson, C. Hamel, et al.
Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews.
BMC Med Res Methodol [Internet], 7 (2007), pp. 10
[201]
M. Castaldo, M. Waliszewska-Prosól, M. Koutsokera, M. Robotti, M. Straburzynski, L. Apostolakopoulou, et al.
Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis.
J Headache Pain [Internet], 23 (2022), pp. 41
[202]
R. Verbeke, I. Lentacker, S.C. De Smedt, H. Dewitte.
The dawn of mRNA vaccines: the COVID-19 case.
J Control Release [Internet], 333 (2021), pp. 511-520
[203]
P. Saluja, G.M. Kohli, A. More, S.B. Shetty, A. Sen.
Bilateral atypical optic neuritis following ChAdOx1_nCoV-19 vaccination: a putative plausibility.
Ocul Immunol Inflamm [Internet], (2022), pp. 1-4
[204]
A. Shafiq, M.A. Salameh, I. Laswi, I. Mohammed, O. Mhaimeed, N. Mhaimeed, et al.
Neurological immune-related adverse events after COVID-19 vaccination: a systematic review.
J Clin Pharmacol [Internet], 62 (2022), pp. 291-303
